ABSTRACT The Ipubi Formation represents the Aptian-Albian siliciclastic-evaporitic succession of Araripe Basin, NE Brazil. This succession comprises siliciclastic rocks (bituminous shales and claystones) and evaporites (gypsum and secondary anhydrite) and represents part of the lacustrine-shallow marine post-rift phase I. This study used sequence stratigraphy concepts to define the relations between changes in the relative lake level and the formation of Ipubi deposits. Results show that the organic-rich shales of the Ipubi Formation formed during a transgressive pulse that covered large areas of the proximal domains. These deposits overlie a regional unconformity that marks the end of the deposition of the underlying Crato Formation. A High Stand stage that followed the transgression influenced the formation of evaporitic deposits. Climate conditions played a major role in influencing the triggering and stopping of evaporite deposition. Thus, a new relative lake level fall event caused the exposure of the Ipubi Formation deposits, and created another regional subaerial unconformity accompanied by widespread karstification of evaporite beds. A posterior transgression caused the deposition of siliciclastic rocks of the Romualdo Formation over the Ipubi Formation strata, and also promoted a new event of karstification of the Ipubi upper evaporite beds.

Nós descrevemos o caso clínico de uma criança do sexo feminino, com 7 anos de idade, portadora de sarcoma de Ewing, que evoluiu com leucemia aguda mielóide pouco diferenciada (LMA-M0) após vinte meses de tratamento utilizando o protocolo EW92. Ela recebeu uma dose total de 1.500 mg de etoposídio, irradiação tumoral na dose total de 35G, e fator de estimulação de colônia granulocítica (G-CSF) conforme programação do protocolo terapêutico. Os exames laboratoriais, por ocasião do diagnóstico da segunda malignidade, mostraram células blásticas imaturas caracterizadas pela expressão de CD34+/CD33-/aMPO+ e a translocação t(4;11) (q 21;q23). A exclusão do G-CSF nos esquemas terapêuticos que associam etoposídio e irradiação tumoral se justifica devido a esta séria complicação no tratamento do sarcoma de Ewing.

We report on a 7-year-old girl with Ewing's Sarcoma (ES) who developed a poorly differentiated acute myeloid leukemia (AML-M0) 20 months after beginning the EW92 protocol for the treatment of the primary tumor. She received a total dose of 1500 mg of etoposide, a tumor cumulative radiation dose of 35Gy and granulocyte colony-stimulating factor (G-CSF) was as predicted in the protocol regimen. At onset of secondary malignancy her laboratorial analysis revealed immature blast cells characterized by CD34+/CD33-/a-MPO+ and a t(4;11)(q21;q23) abnormality. This serious complication of ES treatment, which associates etoposide, irradiation and G-CSF schedule, should be weighed against its therapeutic benefits.